1. Medtech Insight
  2. >>Archive

Renal Denervation: Device Market’s Gold Rush

Three years ago, only Ardian was publicly working on renal denervation devices for hypertension, but at last month’s ACC meeting, some said there were now anywhere from 16 to 40 companies in the space. Fast followers don’t want to miss out on an IP land grab in today’s hottest medical device space.

It’s hard not to see renal denervation as a gold rush of sorts. Three years ago, only Ardian Inc. was publicly working on the new device treatment for resistant hypertension. At March’s annual meeting of the American College of Cardiology, presenters said there were as many as 40 companies staking claims in the space, including Medtronic PLC, St. Jude Medical Inc., Boston Scientific Corp. and a large number of start-ups, all of which are racing to be among the first companies in the market. Overnight, it seems, a nascent field has become crowded and competitive. What happened?

Some eyebrows may have been raised in 2009 when Medtronic and a group of venture investors raised $47 million for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.